Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Virtual Journal Clubs & Case Studies – Engaging Your Advisors Creatively

May 29, 2025 | Advisory Boards, HCP engagement, Impetus Digital, Online advisory board, Pharma trends, Virtual Engagement, Virtual advisory board, advisor engagement, case studies, digital advisory board, hcp trends, journal clubs, life science virtual, medical education, medical training, pharma training 

Creatively engage your advisors while deepening medical understanding! Dive into virtual journal clubs and case studies to analyze patient scenarios, dissect new research, and gain critical feedback on your brand and competitive landscape. It’s medical education and strategic insights combined.

Uncover real-world treatment insights and deepen medical understanding. Explore how virtual journal clubs and case study discussions can revolutionize how you engage your advisors. Learn how to facilitate rich discussions on patient cases, analyze treatment approaches, and critique scientific articles. It’s an effective way to gather critical feedback on your brand, understand the competitive landscape, and provide valuable medical education, all while fostering dynamic advisor engagement.

Virtual Journal Clubs and Case Study Discussions

  • Explore advisors’ treatment approaches for specific patient populations through online case studies.
  • Determine factors influencing treatment decisions and choices between therapies.
  • Facilitate educational opportunities through case-based discussions.
  • Conduct virtual journal clubs to annotate and discuss new articles, gaining feedback on data and competitive insights.

For more creative ways to engage your advisors, visit: https://www.impetusdigital.com/2019/11/15/top-10-creative-ways-to-engage-your-advisors/

Learn more about Impetus Digital’s solutions: www.impetusdigital.com

Schedule a consultation: https://meetwithimpetus.com/

Stay connected:

This content was provided by Impetus Digital

Company Details

- PMLiVE

Impetus Digital

Email
Website

 Latest Content from  Impetus Digital 

Mastering Asynchronous Meetings: Open-Ended Questions – Impetus Digital Tip 1

Unlock the potential of asynchronous virtual meetings with the first tip from our "Top 10 Tips for Optimizing Asynchronous Virtual Meetings".

In-person, hybrid, or digital? State of Pharma meetings and events in 2024

We’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put the idea of in-person meetings being superior to rest.

Navigating Regulatory Challenges – Top 10 Most Important Advisor Questions

This quick video covers #9 of our Top 10 Most Important Advisor Questions, shedding light on the complexities of local and national regulatory issues in the Pharma and Life Sciences...

Top-5 Trends in Virtual KOL Engagement

Register now for one of our upcoming webinars (February 26-28)

Engaging with Different Perspectives – Top 10 Most Important Advisor Questions

In this quick clip, we highlight a vital tip from our 'Top 10 Most Important Advisor Questions' – essential for enhancing your virtual collaboration strategies in Pharma and Life Sciences....

Patient Advocate Engagement: A Customer Story

Learn how our client executed a series of 3 virtual touchpoints with 5 rare disease patient advocates to:- Develop a better understanding of the current treatment landscape and lived patient...

Tailored Marketing Strategies for Pharma – Top 10 Most Important Advisor Questions

In this video, we explore another crucial aspect of advisor questions when developing your virtual advisory board touchpoints – a key component for success in today's diverse healthcare landscape. 7....

Trends in Virtual Collaboration

Join us for a look at the top-5 emerging virtual collaboration trends...

Advisor Questions on Potential Data or Knowledge Gaps

As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here's another one to keep in...

On a journey to diverse, inclusive, and more efficient rare disease trials

Although orphan drugs represent a sizeable portion of new drug approvals, most rare diseases still lack effective treatment. Even more so than for other conditions, rare disease management contains large care...